A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan
Claire F. Verschraegen, Andrzej P. Kudelka, Wei Hu, Monique Vincent, John J. Kavanagh, Evelyne Loyer, Luc Bastien, A. Duggal, R. De Jager
Dive into the research topics of 'A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan'. Together they form a unique fingerprint.